Flag of the European Union EU Clinical Trials Register Help

Clinical trials for roche OR chugai OR genentech

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,190 result(s) found for: roche OR chugai OR genentech. Displaying page 3 of 160.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-004126-10 Sponsor Protocol Number: GO27983 Start Date*: 2012-04-19
    Sponsor Name:Genentech Inc.
    Full Title: A PHASE Ib/II STUDY OF GDC-0068 OR GDC-0980 WITH ABIRATERONE ACETATE VERSUS ABIRATERONE ACETATE IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH DOCETAXEL-BASED CHEMOTH...
    Medical condition: Castration-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GR (Completed) CZ (Completed) ES (Completed) GB (GB - no longer in EU/EEA) NL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004755-39 Sponsor Protocol Number: ML25710 Start Date*: 2012-08-17
    Sponsor Name:Genentech, Inc.
    Full Title: A randomized phase II study of Bevacizumab/mFOLFOX6 vs. Bevacizumab/FOLFIRI with biomarker stratification in patients with previously untreated metastatic colorectal cancer
    Medical condition: Metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) EE (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000425-40 Sponsor Protocol Number: GV29893 Start Date*: 2016-08-03
    Sponsor Name:Genentech Inc.
    Full Title: A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY, ADMINISTERED AS MONOTHERAPY FOR THE TREATMENT OF ACUTE UNCOMPLICATED SEASONAL INFLUENZA A INFECTION...
    Medical condition: acute uncomplicated seasonal influenza
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10022002 Influenza A virus infection LLT
    19.0 100000004862 10022001 Influenza (epidemic) LLT
    19.0 100000004862 10016790 Flu LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-000469-35 Sponsor Protocol Number: GO29227 Start Date*: 2014-08-12
    Sponsor Name:Genentech, Inc.
    Full Title: A RANDOMIZED, PHASE II, MULTICENTER, PLACEBO-CONTROLLED STUDY OF IPATASERTIB (GDC-0068), AN INHIBITOR OF AKT, IN COMBINATION WITH PACLITAXEL AS FRONT-LINE TREATMENT FOR PATIENTS WITH METASTATIC TRI...
    Medical condition: Inoperable locally advanced or metastatic triple negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10027475 Metastatic breast cancer LLT
    17.0 100000004864 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) BE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-002080-10 Sponsor Protocol Number: GO28341 Start Date*: 2013-10-29
    Sponsor Name:Genentech, Inc.
    Full Title: A RANDOMIZED, PHASE II, PLACEBO-CONTROLLED STUDY OF GDC-0068, AN INHIBITOR TO AKT, IN COMBINATION WITH FLUOROPYRIMIDINE PLUS OXALIPLATIN IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC OR G...
    Medical condition: Inoperable locally advanced or metastatic or recurrent gastric or gastroesophageal adenocarcinoma.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10066354 Adenocarcinoma of the gastroesophageal junction LLT
    14.1 100000004864 10071114 Metastatic gastric adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-003449-14 Sponsor Protocol Number: GO41836 Start Date*: 2020-07-14
    Sponsor Name:Genentech Inc.
    Full Title: A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH ATEZOLIZUMAB VERSUS ATEZOLIZUMAB ALONE FOLLOWING ADJUVANT PLATINUM-DOUBLET CHEMOTHE...
    Medical condition: Non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029518 Non-small cell lung cancer stage II PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003756-16 Sponsor Protocol Number: BP43445 Start Date*: 2022-03-18
    Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
    Full Title: A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE MASKED, ACTIVE COMPARATORCONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7200220 ADMINIST...
    Medical condition: Diabetic Macular Edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) CZ (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000568-28 Sponsor Protocol Number: GO28888 Start Date*: 2014-10-16
    Sponsor Name:Genentech, Inc.
    Full Title: A phase II randomized, double-blind study of neoadjuvant letrozole plus GDC-0032 versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early stage breast cancer
    Medical condition: WOMEN WITH ER-POSITIVE/HER2-NEGATIVE, EARLY STAGE BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) DE (Completed) AT (Completed) CZ (Completed) PT (Completed) HU (Completed) IT (Completed) GB (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-003752-21 Sponsor Protocol Number: BN40898(SA-307JG) Start Date*: 2014-05-19
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A multicenter, randomized, addition to baseline treatment, double-blind, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of Satralizumab (SA237) in patients with neuromyelitis...
    Medical condition: Neuromyelitis optica (NMO) and NMO spectrum disorder (MNOSD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10029322 Neuromyelitis optica LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) IT (Completed) PL (Completed) HU (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-002866-21 Sponsor Protocol Number: BH29884 Start Date*: 2016-01-11
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS ...
    Medical condition: Hemophilia A with Inhibitors
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004850 10060612 Hemophilia A LLT
    19.1 100000004850 10053751 Hemophilia A with anti factor VIII LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) PL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003231-19 Sponsor Protocol Number: GO29294 Start Date*: 2015-01-19
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR M...
    Medical condition: Advanced tumor and metastastic disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10046721 Urothelial carcinoma bladder stage III LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Completed) PL (Completed) SI (Completed) SE (Completed) DE (Completed) GB (Completed) HU (Completed) PT (Completed) NL (Completed) FI (Completed) NO (Completed) DK (Completed) BE (Completed) AT (Completed) ES (Completed) FR (Completed) GR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2010-023763-17 Sponsor Protocol Number: GDC4950g Start Date*: 2012-05-18
    Sponsor Name:Genentech, Inc.
    Full Title: A phase II double-blind placebo-controlled randomized study of GDC-0941 or GDC-0980 with Fulvestrant versus Fulvestrant in advanced or metastatic breast cancer in patients resistant to aromatase in...
    Medical condition: Advanced or metastatic breast cancer resistant to aromatase inhibitor therapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) CZ (Completed) GB (Prematurely Ended) DK (Prematurely Ended) HU (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000509-29 Sponsor Protocol Number: BO25734/TDM4997g Start Date*: 2011-12-02
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase III randomized, multicenter, two-arm, open-label trial to evaluate the efficacy of trastuzumab emtansine compared with treatment of physician’s choice in patients with HER2-positive metasta...
    Medical condition: HER2-Positive Metastatic Breast Cancer (MBC)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed) SK (Completed) BE (Completed) CZ (Completed) HU (Completed) NO (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-005490-37 Sponsor Protocol Number: WO29522 Start Date*: 2015-06-11
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH NAB-PACLITAXEL COMPARED WITH PLACEBO WITH NAB-PACLITAXEL FOR PATIENTS WITH P...
    Medical condition: Previously untreated metastatic triple negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) GR (Completed) ES (Ongoing) SE (Completed) DK (Prematurely Ended) LV (Completed) AT (Completed) FI (Completed) CZ (Completed) HU (Completed) PL (Completed) EE (Completed) SI (Completed) FR (Completed) RO (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000335-40 Sponsor Protocol Number: GA29350 Start Date*: 2016-08-23
    Sponsor Name:Genentech, Inc.
    Full Title: A TWO-COHORT RANDOMIZED PHASE II, DOUBLEBLIND, PARALLEL GROUP STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS EVALUATING THE EFFICACY AND SAFETY OF GDC-0853 COMPARED WITH PLACEBO AND ADALIMUMAB ...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-002350-36 Sponsor Protocol Number: GA39925 Start Date*: 2018-09-27
    Sponsor Name:Genentech, Inc.
    Full Title: A PHASE II, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF UTTR1147A COMPARED WITH PLACEBO A...
    Medical condition: Ulcerative colitis (UC)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    20.1 100000004856 10033007 Other ulcerative colitis LLT
    20.1 100000004856 10045366 Ulcerative colitis, unspecified LLT
    20.1 100000004856 10066678 Acute ulcerative colitis LLT
    20.0 100000004856 10075635 Acute hemorrhagic ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) IE (Completed) HU (Completed) NL (Completed) BG (Completed) ES (Ongoing) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001094-33 Sponsor Protocol Number: BO39182 Start Date*: 2016-08-08
    Sponsor Name:Roche Farma, S.A., que representa en España a F. Hoffmann-La Roche Ltd.
    Full Title: A MULTICENTER, OPEN-LABEL, PHASE III STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF EMICIZUMAB GIVEN EVERY 4 WEEKS (Q4W) IN PATIENTS WITH HEMOPHILIA A
    Medical condition: Hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10018938 Haemophilia A (Factor VIII) LLT
    19.0 100000004850 10053751 Hemophilia A with anti factor VIII LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted) PL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006626-26 Sponsor Protocol Number: OSI3364g Start Date*: 2007-07-18
    Sponsor Name:Genentech, Inc.
    Full Title: A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination with Tarceva (erlotinib) Compared With Tarceva Alone For...
    Medical condition: Non-small-cell-lung-cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066490 Progression of non small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) BG (Prematurely Ended) SE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001867-28 Sponsor Protocol Number: MEF4982g Start Date*: 2011-12-19
    Sponsor Name:Genentech, Inc
    Full Title: A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF MEGF0444A DOSED TO PROGRESSION IN COMBINATION WITH BEVACIZUMAB AND FOLFOX IN PATIEN...
    Medical condition: PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000073-21 Sponsor Protocol Number: BH29992 Start Date*: 2016-05-12
    Sponsor Name:Roche Farma, S.A., que representa en España a F. Hoffmann-La Roche Ltd
    Full Title: A SINGLE-ARM, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ONCE WEEKLY SUBCUTANEOUS ADMINISTRATION OF EMICIZUMAB IN HEMOPHILIA A PEDIA...
    Medical condition: Hemophilia A with Inhibitors
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004850 10053753 Hemophilia A without inhibitors LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 26 02:10:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA